Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas

PURPOSE: Neurofibromatosis type 2 (NF2) is a tumor predisposition syndrome characterized by bilateral vestibular schwannomas (VSs) resulting in deafness and brainstem compression. This study evaluated efficacy and biomarkers of bevacizumab activity for NF2-associated progressive and symptomatic VSs....

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Blakeley, Jaishri O., Ye, Xiaobu, Duda, Dan G., Halpin, Chris F., Bergner, Amanda L., Muzikansky, Alona, Merker, Vanessa L., Gerstner, Elizabeth R., Fayad, Laura M., Ahlawat, Shivani, Jacobs, Michael A., Jain, Rakesh K., Zalewski, Christopher, Dombi, Eva, Widemann, Brigitte C., Plotkin, Scott R.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2016
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872317/
https://ncbi.nlm.nih.gov/pubmed/26976425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.3817
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires